AstraZeneca Reports EC Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)

Shots: The EC has approved AstraZeneca’s Saphnelo (anifrolumab; 120mg, SC, QW, PFS) for the treatment of adults with SLE in combination with SoC; regulatory review is ongoing in the US & Japan Approval was based on the P-III (TULIP-SC) trial assessing Saphnelo vs PBO in 367 pts (18-70yrs.) with mod. to sev. active, autoantibody-positive SLE while receiving SoC,…

ByRidhi RastogiDecember 16, 2025

Navigating SLE Care with Saphnelo SC: A Conversation with Pablo Panella from AstraZeneca

Shots: Did you know that patients living with SLE in the EU face a two- to threefold higher risk of mortality compared to the general population? This stark reality underscores the need for therapies that are not only effective but also easier to administer AstraZeneca’s Saphnelo has recently been recommended for approval in the EU as a…

BySaurabh ChaubeyNovember 17, 2025

AstraZeneca Reports Interim P-III (TULIP-SC) Trial Data of Saphnelo for Systemic Lupus Erythematosus (SLE)

Shots: AstraZeneca has reported interim P-III (TULIP-SC) trial data assessing Saphnelo (anifrolumab; 120mg, SC, QW, accessorisedPFS) vs PBO in 367 pts (18-70yrs.) with mod. to sev. active, autoantibody-positive SLE while receiving SoC Interim analysis conducted after the first 220 pts reached Wk. 52, showed Saphnelo reduced disease activity (1EP), measured by BICLA at Wk. 52; data to be…

ByRidhi RastogiSeptember 18, 2025

AstraZeneca Reports EC Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)

Navigating SLE Care with Saphnelo SC: A Conversation with Pablo Panella from AstraZeneca

AstraZeneca Reports Interim P-III (TULIP-SC) Trial Data of Saphnelo for Systemic Lupus Erythematosus (SLE)

Contact US

FOLLOW US